TSUMURA & CO.
4540・Prime Market・Pharmaceuticals
TSUMURA & CO.4540
TSUMURA & CO.4540
Reference Indicators
Market Cap
2,978¥100M
P/E (Forecast)
—
P/B
0.9x
Dividend Yield (Forecast)
4.07%
ROE
9.0%
EV/EBITDA
7.2x
Financial Summary
Unit: ¥M
| Item | 2022Mar 2022 | 2023Mar 2023 | 2024Mar 2024 | 2025Mar 2025 | 2026Mar 2026 |
|---|---|---|---|---|---|
Net Sales | 129,546 | 140,043 | 150,845 | 181,093 | 192,615 |
Cost of Sales | 63,081 | 71,762 | 82,028 | 90,509 | 101,098 |
Gross Profit | 66,465 | 68,281 | 68,816 | 90,583 | 91,516 |
SG&A Expenses | 44,088 | 47,365 | 48,799 | 50,458 | 56,296 |
Operating Income | 22,376 | 20,916 | 20,017 | 40,125 | 35,219 |
Non-operating Income | 3,745 | 2,949 | 3,853 | 3,067 | 7,313 |
Non-operating Expenses | 218 | 412 | 378 | 746 | 2,497 |
Ordinary Income | 25,904 | 23,453 | 23,493 | 42,446 | 40,036 |
Extraordinary Income | 140 | 469 | 462 | 3,248 | 2,194 |
Extraordinary Losses | 481 | 903 | 218 | 135 | 1,194 |
Pre-tax Income | 25,563 | 23,018 | 23,736 | 45,559 | 41,036 |
Income Taxes | 6,167 | 5,632 | 5,689 | 11,035 | 10,793 |
Net Income | 18,836 | 16,482 | 16,707 | 32,428 | 28,117 |
EBITDA | 31,565 | 31,528 | 30,771 | 51,295 | 48,280 |
Gross Margin | 51.3% | 48.8% | 45.6% | 50.0% | 47.5% |
Operating Margin | 17.3% | 14.9% | 13.3% | 22.2% | 18.3% |
ROA | 5.4% | 4.2% | 3.9% | 7.0% | 4.7% |
ROE | 8.2% | 6.7% | 6.4% | 11.3% | 9.0% |